Search by Drug Name or NDC
NDC 69660-0202-91 Rubraca 250 mg/1 Details
Rubraca 250 mg/1
Rubraca is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Clovis Oncology, Inc.. The primary component is RUCAPARIB CAMSYLATE.
MedlinePlus Drug Summary
Rucaparib is used to help maintain the response to other treatments for certain types of ovarian cancer (cancer that begins in the female reproductive organs where eggs are formed), fallopian tube (tube that transports eggs released by the ovaries to the uterus), and primary peritoneal (layer of tissue that lines the abdomen) cancer that has returned in adults who have completely responded or partially responded to other chemotherapy treatment(s). It is also used to treat certain types of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer in people with a specific gene who have received treatment with at least two other chemotherapy treatments. Rucaparib is also used to treat certain types of prostate cancer that has spread to other areas in the body in people with a specific gene who have received other treatments. Rucaparib is in a class of medications called poly (ADP-ribose) polymerase (PARP) inhibitors. It works by killing cancer cells.
Related Packages: 69660-0202-91Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Rucaparib
Product Information
| NDC | 69660-0202 |
|---|---|
| Product ID | 69660-202_0aeb47f7-f854-e93d-e063-6394a90a4350 |
| Associated GPIs | 21535570200325 |
| GCN Sequence Number | 077432 |
| GCN Sequence Number Description | rucaparib camsylate TABLET 250 MG ORAL |
| HIC3 | V1Q |
| HIC3 Description | ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS |
| GCN | 43453 |
| HICL Sequence Number | 044002 |
| HICL Sequence Number Description | RUCAPARIB CAMSYLATE |
| Brand/Generic | Brand |
| Proprietary Name | Rubraca |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | rucaparib |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 250 |
| Active Ingredient Units | mg/1 |
| Substance Name | RUCAPARIB CAMSYLATE |
| Labeler Name | Clovis Oncology, Inc. |
| Pharmaceutical Class | Poly(ADP-Ribose) Polymerase Inhibitor [EPC], Poly(ADP-Ribose) Polymerase Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA209115 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 69660-0202-91 (69660020291)
| NDC Package Code | 69660-202-91 |
|---|---|
| Billing NDC | 69660020291 |
| Package | 60 TABLET, FILM COATED in 1 BOTTLE (69660-202-91) |
| Marketing Start Date | 2017-05-01 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |